Keloid Associated With Ear Piercing
This is a classic keloidal mass, which occur in any ethic group. Because keloids can be intensely painful, they almost always require removal.
Publication date: Available online 19 May 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Hitoshi Maemoto, Shiro Iraha, Ken Arashiroc, Kousei Ishigami, Fumikiyo Ganaha, Sadayuki Murayama
Conditions: Adipose Derived Stem Cells; Keloid Interventions: Procedure: Autologous Adipose Derived stem cell transplantation; Drug: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1 Sponsor: Makerere University Not yet recruiting
Conclusion: Topical FTY720 induces M2 predominance and impairs angiogenesis. Therefore, its local immunosuppressive mechanisms differ from those of conventional immunosuppressive agents. Topical FTY720 can be a novel therapeutic option for abnormal scars that are difficult to control with corticosteroids. Its lymphocytopenic effects may be limited by careful optimization of the treatment regimen. PMID: 32377536 [PubMed - in process]
Conclusions: This review condenses evidence for the active interaction between keratinocytes and fibroblasts in maintaining skin homeostasis and the altered homeostatic interplay between keratinocytes and dermal fibroblasts in scleroderma and scleroderma-like disorders.
IJERPH, Vol. 17, Pages 3229: Effect of Kelulut Honey on the Cellular Dynamics of TGFβ-Induced Epithelial to Mesenchymal Transition in Primary Human Keratinocytes International Journal of Environmental Research and Public Health doi: 10.3390/ijerph17093229 Authors: Abid Nordin Shiplu Roy Chowdhury Aminuddin Bin Saim Ruszymah Bt Hj Idrus Over-induction of epithelial to mesenchymal transition (EMT) by tumor growth factor beta (TGFβ) in keratinocytes is a key feature in keloid scar. The present work seeks to investigate the effect of Kelulut honey (KH) on TGFβ-induced EMT in human primary k...
Publication date: Available online 3 May 2020Source: Life SciencesAuthor(s): Mingyuan Xu, Jiaqi Sun, Yijia Yu, Qianqian Pang, Xiaohu Lin, May Barakat, Rui Lei, Jinghong Xu
In conclusion, miR-4417 and CyclinD1 may be potential therapeutic targets for the treatment of keloid. PMID: 32345773 [PubMed - in process]
Conclusions: High-quality randomized controlled trials are currently lacking, and the existing literature is predominately not specific to use of 5-FU on the face. These studies, however, suggest that intralesional 5-FU is safe and probably more effective than other options in the management of cutaneous scars in the oculofacial region. The delivery methods, timing, dosing, and concomitant therapies were highly variable. Further high-quality controlled studies specific to oculofacial scars may be indicated to assess the efficacy of 5-FU and to establish the best protocols for administering this medication.
The JAK2/STAT3 pathway inhibitor, AG490, suppresses the abnormal behavior of keloid fibroblasts in vitro. Int J Mol Med. 2020 Apr 29;: Authors: Zhou Y, Sun Y, Hou W, Ma L, Tao Y, Li D, Xu C, Bao J, Fan W Abstract AG490 is a selective inhibitor of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. The present study examined its effects on the abnormal behavior of human keloid fibroblasts (HKFs) and evaluated its potential use in the treatment of keloids. Human normal fibroblasts (HNFs) and HKFs were treated with increasing concentrations of...
AbstractBackgroundAlthough keloids and hypertrophic scars are common benign hyperproliferative growths of dermal fibroblasts, the clinical problems including physical and psychological problems are significant and impairing, with few proven treatments. Intralesional triamcinolone acetonide (TAC) and combination of TAC with 5-fluorouracil (5-FU) are widely used to treat keloids and hypertrophic scars, but their efficacy and safety remain controversial.MethodsWe systematically searched MEDLINE, EMBASE, Cochrane Library, and CNKI for relevant trials.ResultsThe mean scar height and the erythema score in the TAC +&thins...